Ciphergen Biosystems announces issuance of European Patent covering a method for aiding bladder cancer diagnosis.
"The issuance of this patent is another example of Ciphergen's growing intellectual property portfolio and the productivity of our collaborations, which continue to support the expansion of our high-value diagnostic development programs," said Gail S. Page, Chief Executive Officer of Ciphergen Biosystems. "In collaboration with our partners, we continue to generate promising biomarker data that may be useful for aiding physicians in cancer diagnosis, disease monitoring, or prediction of recurrence."
The American Cancer Society estimates approximately 67,000 new cases of bladder cancer diagnosed in the United States (about 50,040 men and 17,120 women) in 2007. An estimated 13,750 deaths from bladder cancer will occur this year in the United States (about 9,630 men and 4,120 women).
Ciphergen is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer.
Ciphergen Biosystems, Inc.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||May 1, 2007|
|Previous Article:||Novacea and Schering-Plough enter into worldwide development and commercialization agreement for Asentar.|
|Next Article:||Neuralstem's cells restore motor function in spinal ischemia-paralyzed rats.|